Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2025-07-01 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
美迪西：关于以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Shanghai Medicilon Inc. regarding the progress of its share repurchase program through centralized bidding transactions. It details the repurchase plan, including dates, amounts, prices, and the number of shares repurchased to date. The document references regulatory compliance and previous announcements about the repurchase plan. It does not contain financial statements or earnings data but focuses on the company's share buyback activity. Therefore, this document fits the category of a Transaction in Own Shares (POS) filing, which reports on the company's buyback of its own shares.
2025-07-01 Chinese
美迪西：关于以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of the company's share repurchase program. It details the number of shares repurchased, the price range, total amount spent, and compliance with relevant regulations. It references previous announcements about the share repurchase plan and provides updates on the ongoing buyback activity. The document does not contain financial statements or detailed financial analysis but focuses on the company's transactions in its own shares. Therefore, it fits the category of 'Transaction in Own Shares' (POS). The document length is short and it is not a report publication announcement or regulatory filing. Confidence is high due to clear content and context.
2025-06-03 Chinese
美迪西：关于股东权益变动触及1%暨减持股份结果公告
Major Shareholding Notification Classification · 95% confidence The document is a detailed announcement about a shareholder's equity change and share reduction results. It includes specific data on shareholding before and after the reduction, the reduction plan, implementation results, and compliance with regulations. The document is not a financial report, earnings release, or management discussion. It is focused on the change in major shareholding levels, specifically a shareholder reducing their stake by over 1%. This fits the definition of a Major Shareholding Notification (MRQ). The document length is 2735 characters, which is consistent with a detailed notification rather than a brief announcement or a full report. Therefore, the correct classification is MRQ with high confidence.
2025-05-30 Chinese
美迪西：关于以集中竞价交易方式回购公司股份比例达到1%暨回购进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Shanghai Medicilon Biopharmaceutical Co., Ltd. regarding the progress of its share repurchase program. It details the percentage of shares repurchased (1%), the number of shares, prices, and total amount spent. It references regulatory compliance with stock exchange rules and provides updates on the repurchase progress. The document is relatively short (1649 characters) and focuses on the company's buyback activity rather than financial results or other report types. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buying back or selling its own shares.
2025-05-28 Chinese
美迪西：2024年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2024 Annual General Meeting (AGM) of Shanghai Medicilon Biopharmaceutical Co., Ltd. It includes information about the meeting date, attendance, voting results on various proposals including the annual report, financial statements, director appointments, remuneration, and other corporate matters. The document is not the annual report itself but the official announcement of the voting results and resolutions from the AGM. The length is about 5253 characters, which is consistent with a detailed voting results announcement rather than a full report. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-05-13 Chinese
北京安理（上海）律师事务所关于上海美迪西生物医药股份有限公司2024年年度股东大会的法律意见书
Regulatory Filings
2025-05-13 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.